Eli M. Wallace
CIK: 0001776352
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BridgeBio Oncology Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jan 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
1.1M shares- - Dec 10, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
1.1M shares- - Oct 2, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
1.6M shares- - Aug 26, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
499.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 1,114,400 | - | - | Direct |
| Dec 10, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 1,114,400 | - | - | Direct |
| Oct 2, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 1,614,400 | - | - | Direct |
| Aug 26, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 499,731 | - | - | Direct |
1-4 of 4 transactions
About Wallace Eli M.
Wallace Eli M. (SEC CIK 0001776352) files insider reports with the SEC as Chief Executive Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT).
Signal8 holds 5 ownership filings by Wallace Eli M. (1 Form 3, 4 Form 4), filed between Aug 18, 2025 and Jan 5, 2026. Those filings report 4 transactions, from Aug 26, 2025 to Jan 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Wallace Eli M.'s filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Wallace Eli M.
- Jan 1, 2026: Grant or award of BBOT derivative securities (Form 4, code A).
- Dec 10, 2025: Disposition to issuer transaction of BBOT derivative securities (Form 4, code D).
- Oct 2, 2025: Grant or award of BBOT derivative securities (Form 4, code A).
- Aug 26, 2025: Grant or award of BBOT derivative securities (Form 4, code A).
Other insiders filing for BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Cobo Marc, Principal Accounting Officer
- Elmelech Idan, COO & Principal Financial Ofcr
- Beltran Pedro, President and CEO
- Ben Yong, Chief Med & Dev Officer
- Chen Bihua, Director
- Tipirneni Praveen P., Director